Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, we aim to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. We are applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/10/18 | $54,000,000 | Series A |
Alexandria Real Estate Equities Celgene Corporation Forbion Capital Partners SR One Versant Ventures  | undisclosed |
